Shares of life sciences company Bio-Techne (NASDAQ:TECH) jumped 5.4% in the morning session after TD Cowen reiterated a Buy rating and a $65.00 price target on the stock.
While Bio-Techne stock has underperformed the broader market over the past year, analysts remain moderately bullish about its ...
10d
Merck KGaA: Bio-Techne Acquisition Improves Quality, But The Stock Seems Fully Valued (Downgrade)
Q1 beat and Bio-Techne deal drive upside, but valuation looks full. Read here for a detailed investment analysis.
Germany’s Merck KGaA will buy Bio-Techne Corp. in a deal worth $11.3 billion, one of the largest acquisitions in Minnesota ...
10don MSN
Bio-Techne is a top S&P 500 stock. Germany’s Merck is paying a 24% premium for the company
Bio-Techne stock jumps, with Germany’s Merck KGaA buying the company at a 24% premium.
Detailed price information for Bio-Techne Corp (TECH-Q) from The Globe and Mail including charting and trades.
Detailed price information for Bio-Techne Corp (TECH-Q) from The Globe and Mail including charting and trades.
Halper Sadeh LLC, an investor rights law firm, is investigating the sale of Bio-Techne Corporation (NASDAQ: TECH) to Merck ...
Is TECH a good stock to buy? We came across a bullish thesis on Bio-Techne Corporation on r/ValueInvesting by Dynaheir-be. In this article, we will summarize the bulls’ thesis on TECH. Bio-Techne ...
Shares of Bio-Techne Corp. TECH rallied 5.35% to $57.94 Thursday, on what proved to be an all-around positive trading session for the stock market, with the S&P 500 Index SPX rising 1.08% to 7,500.58 ...
Shares of Bio-Techne Corp. TECH slipped 3.51% to $52.50 Wednesday, on what proved to be an all-around rough trading session for the stock market, with the S&P 500 Index SPX falling 1.62% to 7,266.99 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results